‘Speclipse’ Develops Early Skin Cancer Diagnosis Technology and Receives 3 Billion Won Investment from Soft Bank Ventures
Summary
Soft Bank Ventures has disclosed, together with Interbest, Megainvestment, that they have invested 3 billion won in Speclipse. Before skin cancer symptoms appear or you have a health examination, its currently impossible to diagnose it at the early stages. It will definitely make a great contribution to the medical industry.Soft Bank Ventures investment reviewer Chang Yujin said, Speclipse diagnoses skin cancer accurately according to chemical component analysis and prevents patients from damaging their skin. We look forward to its development in the international medical market.Speclipse representative Byoun Seonghyeon said, Speclipses laser technology brings new opportunities to skin cancer diagnosis. Through this investment, Speclipse will quickly gain overseas certification and marketing, and build up a foundation for its development.